newsfilter
← Latest News
Business Wire·

ISS and Glass Lewis Recommend Forte Biosciences Stockholders Vote FOR Boardroom Change at the Company's Upcoming Annual Meeting

Both Leading Independent Proxy Advisory Firms Conclude Forte's Poor Performance and Dilutive, Anti-Stockholder Actions Under Chairman and CEO Dr. Paul Wagner's Leadership Indicate Boardroom Change is Urgently